These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 15654034)
1. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. Petzold A; Eikelenboom MJ; Keir G; Grant D; Lazeron RH; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G J Neurol Neurosurg Psychiatry; 2005 Feb; 76(2):206-11. PubMed ID: 15654034 [TBL] [Abstract][Full Text] [Related]
2. A comparative study of CSF neurofilament light and heavy chain protein in MS. Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999 [TBL] [Abstract][Full Text] [Related]
3. Axonal pathology in subarachnoid and intracerebral hemorrhage. Petzold A; Rejdak K; Belli A; Sen J; Keir G; Kitchen N; Smith M; Thompson EJ J Neurotrauma; 2005 Mar; 22(3):407-14. PubMed ID: 15785235 [TBL] [Abstract][Full Text] [Related]
4. Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation. Eikelenboom MJ; Uitdehaag BM; Petzold A Mult Scler Int; 2011; 2011():823176. PubMed ID: 22096644 [TBL] [Abstract][Full Text] [Related]
5. Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology. Petzold A; Gveric D; Groves M; Schmierer K; Grant D; Chapman M; Keir G; Cuzner L; Thompson EJ Exp Neurol; 2008 Oct; 213(2):326-35. PubMed ID: 18619438 [TBL] [Abstract][Full Text] [Related]
6. Axonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter. Petzold A; Tozer DJ; Schmierer K Exp Neurol; 2011 Dec; 232(2):234-9. PubMed ID: 21958956 [TBL] [Abstract][Full Text] [Related]
7. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Brettschneider J; Petzold A; Süssmuth SD; Landwehrmeyer GB; Ludolph AC; Kassubek J; Tumani H Mov Disord; 2006 Dec; 21(12):2224-7. PubMed ID: 17013909 [TBL] [Abstract][Full Text] [Related]
8. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388 [TBL] [Abstract][Full Text] [Related]
9. Neurofilament heavy chain and heat shock protein 70 as markers of seizure-related brain injury. Rejdak K; Kuhle J; Rüegg S; Lindberg RL; Petzold A; Sulejczak D; Papuc E; Rejdak R; Stelmasiak Z; Grieb P Epilepsia; 2012 May; 53(5):922-7. PubMed ID: 22509781 [TBL] [Abstract][Full Text] [Related]
10. Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients. Rommer PS; Kamin F; Petzold A; Tumani H; Abu-Mugheisib M; Koehler W; Hoffmann F; Winkelmann A; Benecke R; Zettl UK Mol Diagn Ther; 2014 Dec; 18(6):631-7. PubMed ID: 24986188 [TBL] [Abstract][Full Text] [Related]
11. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. Kuhle J; Regeniter A; Leppert D; Mehling M; Kappos L; Lindberg RL; Petzold A J Neuroimmunol; 2010 Mar; 220(1-2):114-9. PubMed ID: 20117845 [TBL] [Abstract][Full Text] [Related]
12. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Lim ET; Sellebjerg F; Jensen CV; Altmann DR; Grant D; Keir G; Thompson EJ; Giovannoni G Mult Scler; 2005 Oct; 11(5):532-6. PubMed ID: 16193890 [TBL] [Abstract][Full Text] [Related]
13. A specific ELISA for measuring neurofilament heavy chain phosphoforms. Petzold A; Keir G; Green AJ; Giovannoni G; Thompson EJ J Immunol Methods; 2003 Jul; 278(1-2):179-90. PubMed ID: 12957406 [TBL] [Abstract][Full Text] [Related]
14. Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barré syndrome. Dujmovic I; Lunn MP; Reilly MM; Petzold A Muscle Nerve; 2013 Jul; 48(1):132-4. PubMed ID: 23716297 [TBL] [Abstract][Full Text] [Related]
15. Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. Steinacker P; Fang L; Kuhle J; Petzold A; Tumani H; Ludolph AC; Otto M; Brettschneider J PLoS One; 2011; 6(8):e23600. PubMed ID: 21858182 [TBL] [Abstract][Full Text] [Related]
16. Axonal damage and outcome in subarachnoid haemorrhage. Petzold A; Keir G; Kay A; Kerr M; Thompson EJ J Neurol Neurosurg Psychiatry; 2006 Jun; 77(6):753-9. PubMed ID: 16705199 [TBL] [Abstract][Full Text] [Related]
17. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. Trentini A; Comabella M; Tintoré M; Koel-Simmelink MJ; Killestein J; Roos B; Rovira A; Korth C; Ottis P; Blankenstein MA; Montalban X; Bellini T; Teunissen CE J Neurol; 2014 Dec; 261(12):2338-43. PubMed ID: 25228004 [TBL] [Abstract][Full Text] [Related]
19. Neurofilament heavy chain as a marker of neuroaxonal pathology and prognosis in acute encephalitis. Sellner J; Davies NW; Howard RS; Petzold A Eur J Neurol; 2014 Jun; 21(6):845-50. PubMed ID: 24684186 [TBL] [Abstract][Full Text] [Related]
20. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Petzold A; Eikelenboom MJ; Gveric D; Keir G; Chapman M; Lazeron RH; Cuzner ML; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G Brain; 2002 Jul; 125(Pt 7):1462-73. PubMed ID: 12076997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]